GlassScriptPhysician profile
Martins Adeoye
NPI 1962431726
$9,587.17
in general payments reported to CMS, 2019-2025
31 companies · $2,023 in 2025
The $2,023 reported for 2025 was more than what 94% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,554 · 2020: $3,155 · 2021: $490 · 2022: $498 · 2023: $101 · 2024: $1,766 · 2025: $2,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,691 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,690.61 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,633.51 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $972.77 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Allergan, INC. | $633.07 | 2019-2020 | |
| Abbvie INC. | $489.31 | 2021-2025 | |
| Alkermes, INC. | $469.61 | 2019-2025 | Aristada, Lybalvi |
| Indivior INC. | $368.56 | 2019-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $359.24 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $319.35 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $267.47 | 2022-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $218.66 | 2022-2025 | Ingrezza |
| Janssen Scientific Affairs, LLC | $200.00 | 2025 | Spravato |
| Corium, LLC | $192.19 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $176.72 | 2024-2025 | Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $165.19 | 2024-2025 | Auvelity |
| Adlon Therapeutics L.P. | $148.11 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $134.66 | 2024-2025 | Loreev Xr |
| Lundbeck LLC | $128.31 | 2019-2025 | Rexulti |
| Tris Pharma INC | $103.32 | 2024-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $95.37 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $93.38 | 2024-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $85.78 | 2025 | Cobenfy |
| Braeburn INC. | $72.96 | 2025 | Brixadi |
| Orexo US, INC. | $70.65 | 2019-2025 | Zubsolv |
| Sunovion Pharmaceuticals INC. | $43.05 | 2020-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $31.01 | 2025 | Rejoyn |
| Shire North American Group INC | $28.70 | 2019 | |
| Jazz Pharmaceuticals INC. | $27.57 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.86 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $15.96 | 2024 | Quviviq |
| Vertical Pharmaceuticals, LLC | $12.88 | 2019 | |
| Brainsway USA INC | $9.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martins Adeoye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.